Integra Lifesciences Holdings Corp (IART) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

EXHIBIT 99.1

News Release

Contact:

Investor Relations:

Sravan Emany

Sr. Vice President, Strategy, Treasury, Investor Relations

(609) 936-2488

sravan.emany@integralife.com

Michael Beaulieu

Director, Investor Relations

(609) 750-2827

michael.beaulieu@integralife.com

Media:

Laurene Isip

Sr. Director, Global Corporate Communications

(609) 750-7984

laurene.isip@integralife.com

Integra LifeSciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019

Financial Guidance

Fourth Quarter 2018 reported revenue increased 4.0% to $383.3 million; organic revenue increased 4.4%

Fourth Quarter 2018 GAAP earnings per diluted share were $0.29; adjusted earnings per diluted share were $0.65

The Company provides financial guidance for 2019 including total revenue in the range of $1.515 billion to $1.525 billion and organic revenue growth of approximately 5%

Plainsboro, New Jersey, February 21, 2019 -

Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2018, and issued its financial guidance for 2019.

Highlights:


•	Fourth Quarter 2018 Highlights


◦	Reported revenue was $383.3 million, an increase of 4.0% over the prior year, while organic sales were higher by 4.4% over the prior year;


◦	GAAP earnings per diluted share amounted to $0.29, compared to $0.56 in the prior year; fourth quarter adjusted earnings per diluted share amounted to $0.65, compared to $0.64 in the prior year;


•	Full-year 2018 Highlights

The following information was filed by Integra Lifesciences Holdings Corp (IART) on Thursday, February 21, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Integra Lifesciences Holdings Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Integra Lifesciences Holdings Corp.

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/917520/000091752019000013/iart-20181231x10k.htm